You are viewing: Italy Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The Italy Cancer Biomarkers Market was valued at $462 Million in 2026 and projected to reach to $833.1 Million by 2031, representing a compound annual growth rate of 10.3%. Italy's cancer biomarkers market is positioned for sustained growth through 2031, driven by rising cancer incidence rates and the country's commitment to advancing oncology diagnostics.

Italy Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Italy Cancer Biomarkers Market Trends and Insights

  • This expansion reflects Italy's strengthening healthcare infrastructure and increasing adoption of precision oncology diagnostics across Italian medical institutions.
  • Italy's market growth is driven by rising cancer incidence, enhanced reimbursement policies, and growing investment in molecular diagnostics within the Italian healthcare system. The Italian cancer biomarkers sector benefits from a mature healthcare ecosystem and strong regulatory frameworks that support innovation in diagnostic testing.
  • Italy's pharmaceutical and diagnostic companies are increasingly integrating biomarker-driven approaches into clinical practice, supported by collaborations between Italian research institutions and international oncology networks.
  • Between 2026 and 2031, Italy is expected to see accelerated adoption of liquid biopsy technologies and companion diagnostics, positioning the country as a key market within the European cancer biomarkers landscape..

Key Market Statistics

  • CAGR (2026-2031) 10.3% CAGR
  • Market Size, 2026 ~USD 462 Million
  • Forecast, 2031 ~USD 833.1 Million
  • Country Italy

Italy Cancer Biomarkers Market Overview

Market Valuation Growth :

Italy's cancer biomarkers market is valued at $462.0 million in 2026 and is projected to reach $833.1 million by 2031, representing a robust 10.3% CAGR over the forecast period.

Precision Oncology Adoption :

Italian medical institutions are increasingly adopting precision oncology diagnostics, driven by advancements in biomarker testing and growing awareness of personalized cancer treatment approaches across the country.

Healthcare Infrastructure Expansion :

Italy's strengthening healthcare infrastructure and modernization of diagnostic facilities are enabling wider accessibility to advanced cancer biomarker testing across both urban and regional medical centers.

Reimbursement Policy Support :

Enhanced reimbursement policies and favorable healthcare regulations in Italy are supporting market expansion, making cancer biomarker diagnostics more accessible to patients and healthcare providers nationwide.

Italy Cancer Biomarkers Market Dynamics

  • The Italian healthcare system's investment in precision medicine infrastructure and diagnostic capabilities is creating significant opportunities for biomarker adoption across major hospitals and specialized cancer centers.
  • Regulatory support and improved reimbursement mechanisms are facilitating market penetration in both metropolitan and secondary healthcare facilities.
  • The market's 10.3% CAGR reflects Italy's alignment with European standards for personalized cancer care and the increasing demand for early detection and treatment optimization solutions..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • Italy's cancer biomarkers market will grow from $462.0M (2026) to $833.1M (2031) at a 10.3% CAGR.
      • Italy's healthcare system is increasingly adopting precision oncology and molecular diagnostic testing for cancer detection and treatment planning.
      • Liquid biopsy and companion diagnostic technologies are expected to drive significant growth in Italy's market through 2031.
      • Italy's regulatory environment and reimbursement policies support innovation and expansion of biomarker-based cancer diagnostics.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      Italy Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      ITALY: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS130.3140.3153.2167.9204.1226.9253.9284.310.9
      DIAGNOSTIC LABORATORIES315.1335361390.5462.1506.8559.4617.99.4
      OTHER END USERS23.424.225.426.729.831.733.936.36.2
      RESEARCH AND ACADEMIC INSTITUTES77.182.789.898117.9130.4145.2161.810.3
      TOTAL545.9582.2629.4683813.8895.9992.51100.49.8

      Target Audience

      • In Vitro Diagnostics Manufacturers : IVD companies need Italy-specific market data to assess market size, growth potential, and competitive positioning for launching or expanding cancer biomarker diagnostic products in the Italian healthcare market.
      • Pharmaceutical Companies : Pharma firms require detailed Italian market insights to identify companion diagnostic opportunities, understand precision oncology adoption rates, and develop targeted commercialization strategies for oncology drugs.
      • Healthcare Investors & PE Firms : Investment professionals need Italy-focused market analysis to evaluate investment opportunities in diagnostic companies, healthcare providers, and biotech firms operating within the Italian cancer diagnostics sector.
      • Italian Healthcare Providers : Hospitals, cancer centers, and diagnostic laboratories in Italy require market intelligence to benchmark their biomarker testing capabilities, understand adoption trends, and plan diagnostic service expansion.
      • Market Research & Consulting Firms : Research organizations need comprehensive Italy-specific data to support client advisory services, competitive analysis, and strategic planning for healthcare and diagnostics industry stakeholders.

      Key Companies in the Italy Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      Reasons to Buy this Report

      • Italy-Specific Market Sizing : Access precise valuation data for Italy's cancer biomarkers market with detailed 2026-2031 forecasts, enabling accurate business planning and investment decisions tailored to the Italian healthcare landscape.
      • Competitive Landscape Intelligence : Understand the competitive dynamics specific to Italy's market, including key players, market share distribution, and strategic positioning within Italian medical institutions and diagnostic networks.
      • Regulatory & Reimbursement Insights : Gain detailed knowledge of Italy's healthcare reimbursement policies, regulatory frameworks, and compliance requirements that directly impact biomarker adoption and market accessibility across Italian healthcare systems.
      • Growth Driver Analysis : Identify Italy-specific growth catalysts including rising cancer incidence, healthcare infrastructure investments, and precision oncology adoption rates to inform market entry and expansion strategies.
      • Strategic Market Positioning : Develop targeted go-to-market strategies for Italy by understanding regional healthcare provider preferences, diagnostic adoption patterns, and opportunities within Italian hospital networks and cancer centers.

      Frequently asked questions

      What is the current size of Italy's cancer biomarkers market?

      Italy's cancer biomarkers market is valued at $462.0 million in 2026 and is projected to reach $833.1 million by 2031.

      What is the growth rate of Italy's cancer biomarkers market?

      Italy's cancer biomarkers market is expected to grow at a compound annual growth rate (CAGR) of 10.3% from 2026 to 2031.

      What are the main drivers of growth in Italy's cancer biomarkers market?

      Key drivers include rising cancer incidence in Italy, enhanced reimbursement policies, increased adoption of precision oncology, and growing investment in molecular diagnostics within Italian healthcare institutions.

      Which biomarker technologies are gaining traction in Italy?

      Liquid biopsy technologies and companion diagnostics are experiencing accelerated adoption in Italy's cancer biomarkers market, supported by Italian research institutions and international collaborations.

      How does Italy's market compare to other European countries?

      Italy represents a significant market within Europe's cancer biomarkers landscape, with a mature healthcare infrastructure and strong regulatory frameworks that support diagnostic innovation and clinical integration.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status